STOCK TITAN

Erasca, Inc. - ERAS STOCK NEWS

Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.

Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Their mission, embodied in their name, is to 'erase cancer'. The company's innovative approach aims to not just treat but potentially cure cancer by targeting and shutting down the RAS/MAPK pathway, which plays a crucial role in many types of cancer.

Erasca’s robust clinical pipeline includes promising drug candidates such as Naporafenib, a pan-RAF inhibitor with first-in-class potential targeting NRASm melanoma and RAS Q61X tissue agnostic solid tumors. The company's other notable candidates include ERAS-007, a highly selective oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, which target different nodes of the RAS/MAPK pathway. These efforts are supported by recent collaborations with industry giants like Novartis, who are providing crucial compounds like trametinib (MEKINIST®) for combination trials.

On the financial front, Erasca is well-funded with significant investments from both new and existing investors, having recently raised approximately $45 million in a private placement expected to close in April 2024. As of December 2023, the company reported $322 million in cash, cash equivalents, and marketable securities, ensuring a solid runway into the second half of 2026.

Among their latest achievements, Erasca has received FDA Fast Track Designation (FTD) for Naporafenib in combination with trametinib for advanced NRASm melanoma. This designation facilitates accelerated development and review processes, reflecting the potential of their therapies to address unmet medical needs.

The company’s pivotal Phase 3 SEACRAFT-2 trial for Naporafenib in post-immunotherapy settings for NRASm melanoma is slated to begin in the first half of 2024. Additionally, Erasca has announced exciting new partnerships and pipeline enhancements, including in-licensing two preclinical RAS programs, ERAS-0015 and ERAS-4001, to further solidify their leadership in the precision oncology space.

For more up-to-date information on Erasca, Inc., including their latest financial results and key upcoming milestones, visit their official website or recent press releases.

Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) reported promising preliminary data for its lead candidates, ERAS-007 and ERAS-601, demonstrating efficacy in advanced solid tumors. The company signed clinical trial collaboration agreements with Eli Lilly and Pfizer to explore combination treatments with cetuximab and palbociclib, respectively. Erasca's robust balance sheet shows $365 million in cash, ensuring operational funding into mid-2024. However, R&D expenses rose to $28.2 million and net loss was $35.5 million for Q3 2022, though improving from Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.62%
Tags
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) announced a clinical trial collaboration and supply agreement with Pfizer to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with the CDK4/6 inhibitor palbociclib for patients with KRAS- and NRAS-mutant colorectal and pancreatic cancers. This study is part of the Phase 1b/2 HERKULES-3 trial, sponsored by Erasca. Approximately 1.8 million cases of colorectal cancer and 0.5 million cases of pancreatic cancer are diagnosed annually, with a significant portion harboring RAS mutations. The combination aims to enhance treatment efficacy and reduce resistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) announced initial Phase 1/1b data for its ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, showcasing safe profiles for potential combination therapies in solid tumors. ERAS-801, a CNS-penetrant EGFR inhibitor, shows enhanced anti-tumor activity over osimertinib in preclinical models. New KRAS G12D inhibitors demonstrate significant tumor growth inhibition. The company will present findings at the 34th EORTC-NCI-AACR Symposium in October 2022, with further data expected in 2023, highlighting ongoing advancements in their oncology pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
none
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a company dedicated to precision oncology, will participate in the Bank of America Securities Precision Oncology Conference on October 3, 2022, at 3:40 PM ET. CEO Jonathan E. Lim and CFO David M. Chacko will engage in a virtual fireside chat and one-on-one investor meetings. A live webcast will be available, with an archived replay until January 3, 2023. Erasca aims to innovate therapies for RAS/MAPK pathway-driven cancers, leveraging a strong pipeline and expert advisory board to achieve its mission of erasing cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Morgan Stanley Global Healthcare Conference. On September 14, 2022, at 12:55 PM ET, CEO Jonathan E. Lim, M.D., and CFO David M. Chacko, M.D., will engage in a fireside chat at Sheraton Hotel, New York. They will also conduct one-on-one investor meetings. A live webcast will be available, with an archived replay accessible until December 14, 2022. Erasca is focused on therapies for RAS/MAPK pathway-driven cancers, aiming to develop innovative cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences
-
Rhea-AI Summary

Erasca, a clinical-stage precision oncology company, reported promising Phase 1/1b data for its ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in treating RAS/MAPK-altered solid tumors. The retrospective analysis revealed that 23% of patients with non-CRC solid tumors and 44% of those with BRAF-driven tumors responded to these agents. Both drugs demonstrated favorable safety profiles, supporting their combination in upcoming trials. The initiation of the ERAS-007 plus ERAS-601 MAPKlamp trial is anticipated in the first half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.28%
Tags
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) will host a virtual research and development day on September 7, 2022, featuring key opinion leader Dr. David Hong from MD Anderson Cancer Center. The event will present preliminary clinical data for Erasca's lead candidates, the ERK1/2 inhibitor ERAS-007 and the SHP2 inhibitor ERAS-601, targeting advanced solid tumors influenced by the RAS/MAPK pathway. Participants can register online for the event, which will include a live Q&A session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
conferences
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) has entered a five-year collaboration with The University of Texas MD Anderson Cancer Center to evaluate multiple agents targeting the RAS/MAPK pathway. The partnership's initial focus is on ERAS-007, an ERK1/2 inhibitor, and ERAS-601, a SHP2 inhibitor. These will be combined in the first MAPKlamp approach. Ongoing clinical trials of these agents will target various cancers, including non-small cell lung cancer and gastrointestinal malignancies. The collaboration aims to enhance the clinical development of Erasca's pipeline in addressing significant cancer treatment challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS) reported Q2 2022 financial results, showcasing a cash reserve of $391 million. The company is advancing its clinical programs, expecting initial data for ERAS-007 and ERAS-601 by H2 2022. Notable collaborations include partnerships with Eli Lilly and Harvard Medical School to enhance ERAS-007 and ERAS-601's potential. R&D expenses rose to $27.5 million, driven by clinical trials, while G&A expenses increased to $8.4 million. The net loss for the quarter stands at $35.6 million, or $(0.30) per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.35%
Tags
Rhea-AI Summary

Erasca has entered a clinical trial collaboration with Eli Lilly to evaluate ERAS-601, a selective SHP2 inhibitor, in the FLAGSHP-1 trial. This Phase 1/1b trial will assess ERAS-601 combined with Lilly's cetuximab for treating triple wildtype metastatic colorectal cancer and HPV-negative advanced head and neck squamous cell carcinoma. Lilly will provide cetuximab at no cost. The collaboration aims to enhance treatment responses and delay resistance onset in RAS/MAPK driven cancers, addressing significant market needs given the rising case numbers of these malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags

FAQ

What is the current stock price of Erasca (ERAS)?

The current stock price of Erasca (ERAS) is $2.6 as of November 21, 2024.

What is the market cap of Erasca (ERAS)?

The market cap of Erasca (ERAS) is approximately 718.1M.

What is Erasca, Inc.'s primary focus?

Erasca, Inc. is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

What are the key drugs in Erasca’s pipeline?

Key drugs in Erasca's pipeline include Naporafenib, ERAS-007, and ERAS-601 targeting various nodes of the RAS/MAPK pathway.

What recent achievements has Erasca reported?

Erasca has received FDA Fast Track Designation for Naporafenib in combination with trametinib and announced significant collaborations and financial investments.

How is Erasca funded?

Erasca is funded through a combination of private placements and existing investments, with a strong cash position reported at $322 million as of December 2023.

What partnerships has Erasca entered into?

Erasca has partnered with Novartis, among others, to support clinical development of their drug candidates and has in-licensed two preclinical RAS programs.

What is the SEACRAFT-2 trial?

The SEACRAFT-2 trial is a pivotal Phase 3 study evaluating the efficacy of Naporafenib in combination with trametinib for NRAS-mutant melanoma patients post-immunotherapy.

What does FDA Fast Track Designation mean for Erasca?

FDA Fast Track Designation facilitates accelerated development and review processes for Naporafenib in combination with trametinib, aiming to expedite its availability for patients with advanced NRAS-melanoma.

What financial milestones has Erasca achieved recently?

Recently, Erasca secured approximately $45 million in a private placement and reported a strong cash position to fund operations into 2026.

What is the significance of Erasca's mission statement?

Erasca's mission to 'erase cancer' reflects their dedication to creating transformative oncology therapies aimed at not just treating but potentially curing cancer.

How does Erasca's technology target cancer?

Erasca's technology targets the RAS/MAPK pathway, which is critical in many cancers. Their therapies aim to comprehensively shut down this pathway to treat and potentially cure cancer.

Erasca, Inc.

Nasdaq:ERAS

ERAS Rankings

ERAS Stock Data

718.13M
228.31M
12.39%
87.01%
11.67%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO